Nuvation Bio (NUVB) Asset Utilization Ratio: 2025

Nuvation Bio's Asset Utilization Ratio rose 960.21% to 0.03 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.03, marking a year-over-year increase of 960.21%. This contributed to the annual value of 0.01 for FY2024, which is N/A change from last year.
According to the latest figures from Q2 2025, Nuvation Bio's Asset Utilization Ratio is 0.03, which was up 579.50% from 0.00 recorded in Q3 2024.
Nuvation Bio's Asset Utilization Ratio's 5-year high stood at 0.03 during Q2 2025, with a 5-year trough of 0.00 in Q2 2024.
Moreover, its 2-year median value for Asset Utilization Ratio was 0.00 (2024), whereas its average is 0.01.
Data for Nuvation Bio's Asset Utilization Ratio shows a peak YoY surged of 960.21% (in 2025) over the last 5 years.
Over the past 2 years, Nuvation Bio's Asset Utilization Ratio (Quarterly) stood at 0.00 in 2024, then skyrocketed by 960.21% to 0.03 in 2025.
Its last three reported values are 0.03 in Q2 2025, 0.00 for Q3 2024, and 0.00 during Q2 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Summit Therapeutics Inc.	1,387.71B	1,387.50B	-	-
2	BeOne Medicines Ltd.	458.68B	457.16B	1.15B	1
3	Vertex Pharmaceuticals Inc / Ma	102.37B	99.35B	-	0
4	Benitec Biopharma Inc.	65.38B	65.31B	-	-
5	Regeneron Pharmaceuticals, Inc.	60.67B	60.28B	-	0
6	Alnylam Pharmaceuticals, Inc.	60.53B	62.66B	-	1
7	Argenx Se	45.96B	50.00B	-	-
8	INSMED Inc	26.50B	27.40B	-	-
9	BioNTech SE	25.15B	17.24B	-	-
10	Nuvation Bio Inc.	1.42B	1.38B	2.26M	0